Get the Stockscreener App
2.47
8.18%
-0.22
Pre-market:
2.46
-0.01
-0.40%
Jaguar Health Inc stock is traded at $2.47, with a volume of 62,870.
It is down -8.18% in the last 24 hours and down -36.99% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
See More
Previous Close:
$2.69
Open:
$2.66
24h Volume:
62,870
Relative Volume:
0.97
Market Cap:
$1.78M
Revenue:
$29.57M
Net Income/Loss:
$-34.68M
P/E Ratio:
-0.00349
EPS:
-708.7214
Net Cash Flow:
$-7.58M
1W Performance:
-9.52%
1M Performance:
-36.99%
6M Performance:
-93.48%
1Y Performance:
-97.78%
1-Day Range:
$2.43
$2.745
1-Week Range:
$2.43
$2.8999
52-Week Range:
$2.43
$113.91
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
2.47 | 1.78M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases - ACCESS Newswire
Jaguar Health Inc Stock (US47010C1053): Shares Slip As Biotech Valuation Stays Under Pressure - AD HOC NEWS
Jaguar Health Sets $40 Million ELOC and Closes $2 Million Series P Financing - TradingView
Jaguar Health (NASDAQ: JAGX) adds $40M ELOC and $2M preferred deal - Stock Titan
JAGX: Transformative year with major clinical, regulatory, and financial milestones in rare diseases - TradingView
Jaguar Health stock (US47010C1053): Shareholders back financing and governance moves - AD HOC NEWS
Jaguar Health Shareholders Approve Financing and Governance Proposals - TipRanks
Jaguar Health, Inc. announced that it expects to receive $41.99992 million in funding - marketscreener.com
Jaguar Health stockholders approve five proposals at annual meeting By Investing.com - Investing.com Australia
All Jaguar Health (NASDAQ: JAGX) 2026 shareholder meeting proposals pass - Stock Titan
Jaguar Health stockholders approve five proposals at annual meeting - Investing.com
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders - ACCESS Newswire
JAGX Stock Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Animal Health Postpones 2026 Stockholder Meeting Again - The Globe and Mail
Jaguar Health receives Nasdaq delisting notice after share price falls below $1 - Investing.com
Jaguar Health Expects to Release Top Line Results of Crofelemer's Phase 3 Clinical Trial - TMX Newsfile
Jaguar Health Swaps Series Q Preferred for 64,668 Common Shares in Two Streeterville Deals - TradingView
Jaguar Health (JAGX) exchanges Series Q preferred for common and pushes 2026 shareholder meeting - Stock Titan
JAGX Stock Price, Quote & Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health - ACCESS Newswire
Jaguar Health Inc stock (US47010C1053): Q1 2026 update and current valuation picture - AD HOC NEWS
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders - ACCESS Newswire
From Amazon tree latex to trials for children with rare gut failure - Stock Titan
Jaguar Health regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa
Jaguar Health Regains Nasdaq Bid Price Compliance Status - TipRanks
Jaguar Health regains Nasdaq compliance with bid price rule - Investing.com
Jaguar Health regains Nasdaq bid-price compliance, subject to one-year panel monitoring - TradingView
Jaguar Health (JAGX) keeps Nasdaq listing, enters one-year bid price monitor - Stock Titan
Jaguar Health Compliant with Nasdaq Bid Price Rule - marketscreener.com
Drugmaker's revenue jumps 816% as it retains Nasdaq listing - Stock Titan
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... By GuruFocus - Investing.com Canada
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Reven - GuruFocus
JAGX: Q1 2026 net revenue jumped 816% year-over-year, fueled by a major out-license agreement - TradingView
Earnings call transcript: Jaguar Health Q1 2026 revenue surges 816% By Investing.com - Investing.com Nigeria
Earnings call transcript: Jaguar Health Q1 2026 revenue surges 816% - Investing.com
JAGX: Q1 2026 revenue jumped 816% year-over-year, fueled by a transformative licensing deal - TradingView
Q1 2026 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health (JAGX) Q3 2025 Earnings Transcript - AOL.com
Jaguar Health, Inc. Announces Entry Into Material Definitive Exchange Agreements With Streeterville Capital, LLC - Minichart
Jaguar Health Inc (HAM:1JA1) Stock Price, Trades & News - GuruFocus
Jaguar Health (NASDAQ: JAGX) delays 2026 meeting after Nasdaq talks - Stock Titan
Jaguar Health Inc stock (US47010C1053): Q1 2026 revenue surge draws volatile market reaction - AD HOC NEWS
Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key - Bez Kabli
JAGX Sees Dramatic Revenue Surge in Q1 2026 - GuruFocus
JAGX Financials: Income Statement, Balance Sheet & Cash Flow | Jaguar Health Inc - Stock Titan
Jaguar Health Reports First Quarter 2026 Financials - ACCESS Newswire
JAGX: Net revenue jumped 816% year-over-year, fueled by a major licensing deal and strategic refocus - TradingView
Jaguar Health reports Q1 2026 revenue up 816% to $20.3M, operating income $10.2M - TradingView
Jaguar Health licenses U.S. Mytesi rights in $19M Q1 deal - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jaguar Health (NASDAQ: JAGX) posts 816% Q1 2026 revenue surge - Stock Titan
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):